Capricor Therapeutics, INC Form 4 insider transactions

Frank Litvack, a director at Capricor Therapeutics, reported the acquisition of stock options and adjustments to his holdings of common stock.

Capricor Therapeutics' Chief Financial Officer, Anthony Bergmann, acquired shares and stock options on January 2, 2025, according to a recent SEC filing.

Karen Krasney, EVP and General Counsel at Capricor Therapeutics, was granted 60,000 stock options on January 2, 2025.

Capricor Therapeutics CEO Linda Marban was granted stock options for 244,962 shares on January 2, 2025, according to a recent SEC filing.

A director at Capricor Therapeutics, Inc. has been granted stock options as part of their compensation for board and committee service.

A Capricor Therapeutics director, Paul Gisbert Auwaerter, acquired stock options for 19,130 shares on January 2, 2025, as part of his board service compensation.

A Capricor Therapeutics director, Karimah Es Sabar, was granted stock options for board service, including both vesting and fully vested options.

Director David B. Musket of Capricor Therapeutics acquired stock options for 24,170 shares on January 2, 2025, as part of his annual board service and committee service.

Director George W. Dunbar Jr. of Capricor Therapeutics, Inc. reported the acquisition of stock options on January 2, 2025, related to board and committee service.

Director Earl M. Collier Jr. of Capricor Therapeutics was granted multiple stock options on January 2, 2025, as part of his annual board service and committee service.

Director Philip J. Gotwals of Capricor Therapeutics acquired stock options for 19,850 shares on January 2, 2025, with varying vesting schedules.

Karen Krasney, EVP and General Counsel at Capricor Therapeutics, exercised stock options and acquired 8,000 shares of common stock.

Director Frank Litvack acquired 20,391 shares and warrants of Capricor Therapeutics, increasing his indirect holdings.

Nippon Shinyaku Co Ltd acquired 2,798,507 shares of Capricor Therapeutics' common stock via a private placement on September 20, 2024, increasing its holdings to 7,090,351 shares.

Director David B. Musket exercised stock options to acquire 34,000 shares of Capricor Therapeutics common stock at $1.39 per share on August 7, 2024.

Earl M Collier Jr., a director at Capricor Therapeutics, exercised stock options to acquire 30,000 shares of common stock at $1.39 per share on April 23, 2024.

David B. Musket, a director at Capricor Therapeutics, exercised stock options to acquire shares at $1.39 per share on April 23, 2024.